• Wion
  • /World
  • /European countries to resume J&J COVID vaccine deliveries

European countries to resume J&J COVID vaccine deliveries

European countries to resume J&J COVID vaccine deliveries

Vials labelled "COVID-19 Coronavirus Vaccine" and sryinge are seen in front of displayed Johnson&Johnson logo in this illustration taken, February 9, 2021.

Europeancountriesprepared on Wednesday toresumedeliveriesof Johnson & Johnson'sCOVID-19vaccineand speed up the rollout after Europe's drug regulator backed the shot.

Germany's health ministry said it would startdeliveriesto federal states for use in vaccination centres shortly, and that family doctors should receive thevaccinefrom week after next.

TheEuropeanMedicines Agency (EMA) said on Tuesday that it had found a possible link between J&J'svaccineand rare blood clotting issues in adults who received doses in the United States, but it said that benefits of the one-dose shot outweigh its risks.

Add WION as a Preferred Source

The review of a handful of cases prompted a pause in the rollout of the J&Jvaccinein Europe and the United States last week, the latest setback to efforts to tackle the pandemic, which has killed more than 3.1 million and infected 142.1 million worldwide.

While the EMA said it considers thevaccinesafe, it has left it up to theEuropeanUnion's member states to decide how to use it, taking a similar stance to that with rival AstraZeneca's shot.

The Netherlands plans toresumethe use of thevaccineas of Wednesday. Italy's health ministry recommended that the J&Jvaccinebe used for people over the age of 60.

In Germany, it was not immediately clear whether regulators would limit the use of J&J'svaccineto a certain age group, as it had done with thevaccineby AstraZeneca, which itsvaccinecommittee recommends for ages 60 and over. The committee, known as STIKO, is due to meet on Thursday.

Denmark's health authority expects to announce its decision next week on how to proceed, pending further investigations into thevaccine's possible link to rare blood clots.

Use of the J&Jvaccinewas temporarily halted by USregulators last week after rare brain blood clots combined with a low blood platelet count were reported in six women, prompting the company to delay its rollout in Europe. Nearly 8 million people in the United States have received the J&Jvaccine.

J&J has said it is working closely with regulators and noted that no clear causal relationship had been established between the clotting cases and its shot.